Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study

Xianmin Meng, Qianqian Wang, Shunquan Wu, Di Pu, Amber Zhang, Sun Fang, Xuan Zhou, Hongzhou Lu, Xianmin Meng, Qianqian Wang, Shunquan Wu, Di Pu, Amber Zhang, Sun Fang, Xuan Zhou, Hongzhou Lu

Abstract

Introduction: Belimumab is a recombinant human immunoglobulin G1λ monoclonal antibody indicated as an intravenous (IV) 10 mg/kg and subcutaneous (SC) 200-mg dose for the treatment of systemic lupus erythematosus (SLE). Belimumab 10 mg/kg IV has been approved for the treatment of patients with SLE in China. This phase 1 study investigated the pharmacokinetics (PK), safety, and tolerability of belimumab 200 mg SC and the approved IV formulation in a healthy Chinese population.

Methods: This was a 13-week open-label, randomized, parallel-group study in healthy Chinese volunteers. Eligible volunteers were randomized (1:2) to receive a single dose of IV or SC (via auto-injector) belimumab 200 mg. PK and safety endpoints were evaluated using descriptive statistics.

Results: Thirty-six healthy Chinese volunteers were enrolled and all completed the study. Concentration-time profiles were as expected for both formulations. Overall, 130 adverse events (AEs) were reported, with 28 AEs reported in 11 (91.7%) volunteers in the IV group and 102 AEs in 24 (100%) volunteers in the SC group. Of the 130 AEs, 104 (80.0%) were considered to be treatment-related (27 [20.8% of total AEs] treatment-related AEs in the IV group; 77 [59.2% of total AEs] in the SC group). Although the occurrence of AEs was higher in the SC group, most volunteers (91.7%) experienced AEs of mild intensity. The most frequently reported AEs included injection site pain (n = 19 [79.2%]) and oropharyngeal pain (n = 5 [20.8%]) in the SC group, and positive bacterial test, upper respiratory tract infection, blood uric acid increase, white blood cell count increase, asthenia, and diarrhea (n = 2 [16.7%], each) in the IV group.

Conclusions: PK profiles of 200 mg SC and IV belimumab administrations were similar to previous studies, and safety profiles were acceptable, supporting the use of the SC dose in Chinese patients with SLE.

Trial registration: NCT04136145.

Keywords: Belimumab; Intravenous; Monoclonal antibody; Pharmacokinetics; Safety; Subcutaneous; Systemic lupus erythematosus.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Study design. IV intravenous, SC subcutaneous
Fig. 2
Fig. 2
Mean (+ SD) belimumab concentration–time plots for the belimumab 200 mg IV and SC treatment groups (a linear and b semi-log; PK population; IV, n = 12; SC, n = 24). IV intravenous, PK pharmacokinetic, SC subcutaneous, SD standard deviation

References

    1. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328–2337. doi: 10.1002/art.34400.
    1. Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res. 2012;64:132–137. doi: 10.1002/acr.20648.
    1. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48:673–675. doi: 10.1093/rheumatology/kep062.
    1. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology. 2012;51:491–498. doi: 10.1093/rheumatology/ker368.
    1. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930. doi: 10.1002/art.30613.
    1. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013;24:1357–1366. doi: 10.1681/ASN.2013010026.
    1. Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355–363. doi: 10.1136/annrheumdis-2017-211631.
    1. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15:633–643. doi: 10.1177/0961203306071710.
    1. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009;5:400–404. doi: 10.1038/nrrheum.2009.106.
    1. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65:753–763. doi: 10.1002/art.37795.
    1. Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus. 2013;22:99–105. doi: 10.1177/0961203312463110.
    1. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. Scand J Rheumatol. 1998;27:98–105. doi: 10.1080/030097498440958.
    1. Somers EC, Thomas SL, Smeeth L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum. 2007;57:612–618. doi: 10.1002/art.22683.
    1. Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf. 2006;15:656–661. doi: 10.1002/pds.1199.
    1. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75:136–141. doi: 10.1136/annrheumdis-2014-206334.
    1. Shim JS, Sung YK, Joo YB, Lee HS, Bae SC. Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int. 2014;34:909–917. doi: 10.1007/s00296-013-2915-9.
    1. Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000–2006. J Rheumatol. 2008;35:1978–1982.
    1. Mok CC. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. Lupus. 2011;20:767–771. doi: 10.1177/0961203310388447.
    1. Kang SC, Hwang SJ, Chang YS, Chou CT, Tsai CY. Characteristics of comorbidities and costs among patients who died from systemic lupus erythematosus in Taiwan. Arch Med Sci. 2012;8:690–696. doi: 10.5114/aoms.2012.30293.
    1. Yu KH, See LC, Kuo CF, Chou IJ, Chou MJ. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res. 2013;65:244–250. doi: 10.1002/acr.21820.
    1. Wang Z, Wang Y, Zhu R, Tian X, Xu D, Wang Q, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine. 2015;94:e794. doi: 10.1097/MD.0000000000000794.
    1. Golder V, Connelly K, Staples M, Morand E, Hoi A. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus. 2013;22:1425–1430. doi: 10.1177/0961203313500547.
    1. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066–1073. doi: 10.1172/JCI38010.
    1. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5:564–576. doi: 10.1038/nrd2085.
    1. GlaxoSmithKline. Belimumab European Union summary of product characteristics. . Accessed 9 Nov 2020.
    1. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377:721–731. doi: 10.1016/S0140-6736(10)61354-2.
    1. Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:1016–27. doi: 10.1002/art.40049.
    1. Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1125–34. doi: 10.1002/art.40861.
    1. GlaxoSmithKline. Belimumab US prescribing information. . Accessed 9 Nov 2020.
    1. GlaxoSmithKline. Belimumab Canada product monograph. . Accessed 9 Nov 2020.
    1. GlaxoSmithKline. Belimumab Japan results of deliberation. . Accessed 9 Nov 2020.
    1. GlaxoSmithKline. Benlysta, the world’s first biologic therapy for the treatment of systemic lupus erythematosus (SLE), now approved in mainland China. . Accessed 09 Nov 2020.
    1. GlaxoSmithKline. The world’s first biologic therapy for patients with SLE, Benlysta receives NMPA approval for children with lupus aged five years and above. . Accessed March 2021.
    1. Struemper H, Thapar M, Roth D. Population pharmacokinetic and pharmacodynamic analysis of belimumab administered subcutaneously in healthy volunteers and patients with systemic lupus erythematosus. Clin Pharmacokinet. 2018;57:717–28. doi: 10.1007/s40262-017-0586-5.
    1. McKenzie B. Clinical trials handbook - Asia Pacific. . Accessed August 2021.
    1. Shida Y, Takahashi N, Sakamoto T, Ino H, Endo A, Hirama T. The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. J Clin Pharm Ther. 2014;39:97–101. doi: 10.1111/jcpt.12101.
    1. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558. doi: 10.1038/clpt.2008.170.
    1. Yapa SW, Roth D, Gordon D, Struemper H. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. Lupus. 2016;25:1448–1455. doi: 10.1177/0961203316642309.
    1. Cai WW, Fiscella M, Chen C, Zhong ZJ, Freimuth WW, Subich DC. Bioavailability, pharmacokinetics, and safety of belimumab administered subcutaneously in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:349–57. doi: 10.1002/cpdd.54.
    1. Cuadrado MJ, Calatayud I, Urquizu-Padilla M, Wijetilleka S, Kiani-Alikhan S, Karim MY. Immunoglobulin abnormalities are frequent in patients with lupus nephritis. BMC Rheumatol. 2019;3:30. doi: 10.1186/s41927-019-0079-2.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir